Centre for Brain Research, IISc
 

 

Faculty

Rahul Kumar's Lab

Home

rahul

Rahul Kumar, PhD

Assistant Professor Grade I at the Centre for Brain Research

Profile:

Rahul did his MSc (Biotechnology) from AIIMS, New Delhi (2010) and PhD (Bioinformatics) from CSIR-IMTECH, Chandigarh (2015). In his PhD, he worked on developing biological databases and machine learning based prediction models to design anticancer therapeutics. Then he joined Institute of Cancer Research (ICR), London and worked on identification of synthetic lethal interactions using high throughput genomic technologies. Then he joined Memorial Sloan Kettering Cancer Center (MSKCC), New York and worked on genetics of rare form of breast cancers to identify their putative genetic drivers. Later he joined Columbia University Irving Medical Center (CUIMC), New York as a scientist and focused on non-coding genome of diffuse large B-cell lymphoma (DLBCL). Rahul joined CBR in 2021 and his research focus is on non-coding genome of glioblastoma multiform (GBM) and other brain related diseases.

Research

This will be updated soon.

 

People

This will be updated soon.

Position

We are looking for enthusiastic candidates to join our lab who are interested to work on the computational genomics aspects of neurological disorders e.g. Alzheimer’s disease, Parkinson disease and other forms of dementia. We are specifically interested in GWAS studies using large population cohorts. Our lab is also interested in working on identification of non-coding elements as putative genetic drivers of glioblastoma and other form of brain tumors. Candidates with background in bioinformatics would be preferable.

Currently, we are looking for postdoctoral candidates interested in applying for SERB-National Post Doctoral Fellowship (N-PDF) in upcoming application cycle (3 May 2021). Research proposal should align with lab and CBR interest (broad area could be as mentioned above).

Interested candidates may send their CV along with cover letter at kumarrahul[at]iisc.ac.in

Publications

  1. Riaz N., Sherman E., …Kumar R., et al (2020). Precision Radiotherapy: Reduction in Radiation for Oropharyngeal Cancer in the 30 ROC Trial. JNCI: Journal of National Cancer Institute.

  2. Pareja, F., Lee J. Y., Gularte-Mérida, R., Selenica P., Brown, D.N., Da Cruz Paula, A.,Kumar R., et al (2019). The genomic landscape of mucinous breast cancer.JNCI: Journal of National Cancer Institute.111:737:74.

  3. Pareja, F., …Kumar R., et al (2019). Loss-of-function mutations in the pH regulators ATP6AP1 and ATP6AP2 in granular cell tumors. 9:3533. Nature Communications

  4. Mandelker, D.L.*,Kumar R.*, Weigelt, B.* et. al. (2019). The Landscape of Somatic Genetic Alterations in Breast Cancers from CHEK2 Germline Mutation Carriers. JNCI Cancer Spectrum3(2):pkz027.

  5. Selenica P.*, Raj N.*,Kumar R.*,et. al. (2019).Solid pseudopapillary neoplasm of the pancreas are dependent on the Wnt pathway. Molecular Oncology. 13:1684-1692.

  6. Weigelt, B.*, Bi, R.*,Kumar R.*, et. al. (2018)., The Landscape of Somatic Genetic Alterations in Breast Cancers From ATM Germline Mutation Carriers. JNCI: Journal of National Cancer Institute.110:1030-1034.

  7. Ashley C., Paula A. D. C., Kumar R. , et. al. (2018), Analysis of mutational signatures in primary and metastatic endometrial cancer reveals distinct patterns of DNA repair defects and shifts during tumor progression. Gynecologic Oncology.152(1):11-19.

  8. Mueller, J.J., Schlappe, B.A.,Kumar R.,et. al.(2018). Massively parallel sequencing analysis of mucinous ovarian carcinomas: genomic profiling and differential diagnoses. Gynecologic Oncology.150, 127–135.

  9. Brough, R., Gulati, A., Haider, S., Kumar R., et. al. (2018). Identification of highly penetrant Rb-related synthetic lethal interactions in triple negative breast cancer. Oncogene.

  10. Geyer, F.C., …Kumar R., et. al. (2018). Recurrent hotspot mutations in HRAS Q61 and PI3K-AKT pathway genes as drivers of breast adenomyoepitheliomas. Nature Communications.9:1816

  11. Bajrami, I., ….Kumar R., et. al. (2018). E-Cadherin/ROS1 Inhibitor Synthetic Lethality in Breast Cancer.Cancer Discovery. 8, 498–515.

  12. Nikkilä, J.,Kumar R., et. al. (2017). Elevated APOBEC3B expression drives a kataegic-like mutation signature and replication stress-related therapeutic vulnerabilities in p53-defective cells.British Journal of Cancer117, 113–123.

  13. Kumar R., and Raghava, G.P.S. (2016). ApoCanD: Database of human apoptotic proteins in the context of cancer.Scientific Reports117, 113–123.

  14. Singh Nanda,J.*,Kumar R., et. al. (2016). dbEM: A database of epigenetic modifiers curated from cancerous and normal genomes.Scientific Reports6, 19340.

  15. Kumar R., et. al. (2014a). Designing of promiscuous inhibitors against pancreatic cancer cell lines.Scientific Reports4, 4668.

  16. Kumar R., et. al. (2013a). CancerDR: Cancer Drug Resistance Database.Scientific Reports3, 1445.

  17. Kumar R., et. al. In Silico Designing and Screening of Antagonists against Cancer Drug Target XIAP.Current Cancer Drug Targets 15, 836–846.

  18. Holmes A. B., Corinaldesi C., Shen Q., Kumar R. Single-cell analysis identifies subpopulations of germinal-center B-cells informing on lymphoma cell-of-origin and outcome.Journal of Experimental Medicine.

Google Scholar profile: Link for the Google Scholar Profile

Contact

Centre for Brain Research
Indian Institute of Science (IISc)
Malleswaram 18th Cross
Bangalore-560012
Karnataka, INDIA.

Email: kumarrahul[at]iisc.ac.in
Telephone: Office +91 80 2293 3659